Editorial Advisory Board

Drug Discovery World is under the editorial guidance of Dr. Roger Brimblecombe (ex Chairman Smith Kline & French Research).Dr Brimblecombe brings a wealth of experience to Drug Discovery World.

He is the former Chairman of Smith Kline & French Research Ltd and held various Vice-Presidential posts within the SmithKline Corporation. Subsequently he has been Chairman of Vanguard Medica Ltd, Core Group plc, Oxford Asymmetry Ltd, Oxxon Pharmaccines Ltd, DanioLabs Ltd, MVM Ltd and M&E Biotech A/S (Denmark). He has also served as a Non Executive Director of a number of biotech companies in the US, Europe, Singapore and Australia.

He recently retired from the post of Executive Chairman and CEO of pSivida Ltd. He retains Non Executive Directorships of Vertex Pharmaceuticals Inc (US), Vertex Pharmaceuticals (Europe) Ltd and Tissue Science Laboratories plc and is a Partner in MVM Life Science Partners LLP. He is also a Non Executive Director of the Gloucestershire Partnership NHS Trust.

He has been Chairman of the Society of Pharmaceutical Medicine and of the Scientific Committee of the Association of British Pharmaceutical Industry and also a member of the Councils of the Royal College of Pathologists and the Institute of Biology.

Other Members of the Advisory Panel:

Dr Steve Arlington
Dr Arlington has more than 10 years' experience in pharmaceutical research and development both as a project team leader and research group manager resulting in the development and launch of a number of world class drugs and diagnostic tests.
As a partner of PricewaterhouseCoopers and global leader of the Pharma R&D practice, with total responsibility for the European pharmaceutical business, Dr Arlington has acquired a further 15 years experience working extensively with company boards and senior management in the areas of R&D and e-Business strategy.

Dr Nigel Brown
Dr. Brown received his bachelor's degree (chemistry) and his doctorate (natural products metabolism) from the University of Oxford, England, funded by the U.S. National Institutes of Health. He was subsequently awarded a Nestlé postdoctoral fellowship at Massachusetts Institute of Technology, where his research focused on the cancer-forming potential of several common food products. He joined the Department of Drug Metabolism and Pharmacokinectics at The Upjohn Company in 1991, where he supported drug metabolism research and first-in-human clinical trials.
In 1993 Dr Brown moved to SmithKline Beecham R&D where he played a key role in introducing LC/MS/MS as the principal analytical tool for metabolic and pharmacokinetic assessment. In 1997 Dr. Brown joined Phoenix International Life Sciences, a high-growth CRO, in a general management capacity overseeing preclinical operations. Following the acquisition of Phoenix International by MDS, Dr. Brown ran MDS Pharma Service's global preclinical enterprise.

After receiving his MBA, Dr. Brown transitioned his focus to Corporate Strategy and M&A within the CRO sector. He has worked for Covance since June 2006 as head of corporate development and strategy. Dr. Brown sits on the management team of Covance Inc., serves on the boards of several healthcare companies, and has published broadly in scientific and business journals. Dr Brown is based in Princeton, New Jersey.

Dr George Poste
Dr. Poste is CEO of Health Technology Networks, a healthcare consulting group based in Scottsdale, Arizona specializing in the impact of genetics, computing and other advanced technologies on health care R&D and Internet-based systems for healthcare delivery. From 1992 to 1999 he was President, R&D and Chief Science and Technology Officer at SmithKline Beecham PLC and a member of the Board of Directors. During his tenure in the pharmaceutical industry he was associated with 29 successful drug and vaccine registrations in the USA and internationally. He is non-executive Chairman of diaDexus, the joint venture in molecular diagnostics between SB and Incyte Pharmaceuticals, and non-Executive Chairman of Structural GenomiX. He serves on the Board of Directors of Maxygen and Illumina. He has recently been appointed Chairman of Orchid Biosciences. He received a Doctorate in Veterinary' Medicine in 1966 and a Ph.D. in Virology in 1969 from the University of Bristol. He is a Board-certified Pathologist, Fellow of the Royal College of Pathologists, Fellow of The Royal Society and a Founder Fellow of the Academy of Medical Sciences in the UK. Dr. Poste was awarded the honor of Commander of the Order of the British Empire (CBE) by Queen Elizabeth II in 1999.
He is a Research Professor at the University of Pennsylvania, the William Pitt Fellow at Pembroke College, Cambridge University and a Fellow of University College, London.
He has published over 300 scientific papers and co-edited 15 books, primarily in the fields of cancer research and drug delivery. He is co-founder of Cancer and Metastasis Reviews and Advanced Drug Delivery Reviews, a past Chairman of the Editorial Board of the journal Nature BioTechnology, serves on the editorial boards of several journals and also writes a regular column for the Financial Times.
He has served on government committees for the National Institutes of Health, Office of Technology Assessment (OTA) and the Departments of State, Commerce and Defense, and is a member of the U.S. Defense Science Board at the Pentagon.

Dr David Clough
Dr Clough was the Director of Research of Roche UK and also a member of the Roche International Research Executive. He was involved in the discovery of the HIV protease inhibitor Invirase and Roche's MMP inhibitor Trocade. Now running his own consultancy Dr Clough is also a member of the Scientific Advisory Board for Cambridge Antibody Technology as well as a member of the ABPI R&D Committee, the British Pharmacology Society and the CMR Innovation Board.

Dr Gregory Lennon
Dr. Lennon has over 20 years of experience translating genomic research to biotechnology discovery. He was the CEO and founder of Endogeny Bio, a biopharmaceutical company developing a new class of therapeutic that acts directly on a patient's endogenous multipotential cells. Prior to Endogeny Bio, Dr. Lennon served as a Venture Partner with several venture capital firms, after having been the Chief Scientific Officer at Gene Logic. He is also known as a founder of the I.M.A.G.E. Consortium, the largest collection of public cDNA clones, and was a senior scientist at the Lawrence Livermore National Laboratory and with the US Department of Energy's Joint Genome Institute. Dr. Lennon received a Ph.D. in Genetics from the University of Pennsylvania, has published over 75 articles, and serves on several corporate Boards.

Dr Keith Mansford
Dr Keith Mansford spent most of his career with Beecham Group where he latterly had full executive responsibility for the Research & Development organisation. He was a member of the merger team which successfully negotiated the Beecham-SmithKline merger and finally retired from SmithKline-Beecham plc as Chairman, Research & Development in 1992. He is currently Chairman of Kudos Pharmaceuticals as well as Mansford Associates, a specialised international healthcare consultancy, whilst also serving as Non-Executive Director of Skye Pharma plc, CRC Technology, Gemini Research Ltd and Proteome Sciences plc.

Dr David U'Prichard
Dr David U'Prichard is currently President of Druid Consulting LLC, a pharmaceutical and biotechnology-consulting firm, providing customized services to life sciences clients in the United States and Europe. He is also a Venture Partner with Care Capital LLP and Red Abbey Venture Partners, private equity providers.

Previously David was Chief Executive Officer of 3-Dimensional Pharmaceuticals, Inc. from 1999 to 2003. In addition, he held a variety of positions within the pharmaceutical and biotechnology industries, including, President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals; Executive Vice President and International Research Director, and a Member of the Board of Zeneca Pharmaceuticals; General Manager, Research Department, ICI Pharmaceuticals, and Vice President Biomedical Research, ICI Pharmaceuticals; and Senior Vice President and Scientific Director for Nova Pharmaceutical Corporation.

At board level, David is a director of Invitrogen Corp. and non-executive Chairman of Cyclacel. He was Chairman of the Pennsylvania Biotechnology Association in 2004-2005 and from 1992 to 1997 he was a member of the board of the Biotechnology Industry Organization (BIO).

David received a BSc in Pharmacology from University of Glasgow in 1970 and a PhD in Pharmacology from University of Kansas in 1975.

Dr Timothy Wells
Dr Wells is currently CSO at MMV. Dr Wells is a well-established figure in commercial discovery research circles and has more recently established a reputation as advisor to key philanthropic donors in their malaria research and development investments.

Previously, Dr Wells was Senior Executive Vice President Research at the former Serono Group, and a member of its Executive Management Board reporting to the CEO. He was responsible for two Strategic Management Committees: the Research Strategic Committee - managing projects from discovery until proof of concept in vivo, and the Early Development Strategic Committee - with responsibility until proof of concept in humans.

Dr Wells holds a Ph.D in Chemistry from the Imperial College of Science and Technology in the UK. He is a Fellow of the Royal Society of Chemistry, a Member of the Biomedical Society in the UK, and serves on several research Advisory Boards.

Dr Rene Ziegler
As the Head of Research Information Management at Novartis Pharma AG, Dr Ziegler has a major input into the global IT strategy and implementation of this major pharmaceutical group. Previous to Novartis he was the head of numerous preclinical research departments at Sandoz Pharma and was the Head of the Research IT Integration Task Force for the merging of Ciba and Sandoz into Novartis.

Professor Stephen Naylor
Professor Stephen Naylor is currently Adjunct Professor of Genetics and Genomics at Boston University School of Medicine (Boston, MA), as well as a Visiting Faculty Member in the Division of Biological Engineering at MIT (Cambridge, MA) and a Faculty Member of the Computational Systems Biology Initiative (CSBi) also at MIT. He is the former Chief Technology Officer (CTO), and Senior Vice President for Research at Beyond Genomics, a Systems Biology company based in Waltham, MA, where in concert with his colleagues, he built the worlds first integrated systems biology platform, consisting of both analytical, bioinformatic and knowledge assembly capability. In addition as part of the Business Development team he was responsible for helping to raise $28M in venture capital, and alliance partnerships as well as $12M in grants (in conjunction with partners at Boston University School of Medicine). Previously he was the founding Director of the Biomedical Mass Spectrometry and Functional Proteomics Center at Mayo Clinic. In addition he was Professor of Biochemistry and Molecular Biology, and Professor of Molecular Pharmacology and Experimental Therapeutics. He was also Adjunct Professor of Clinical Pharmacology, as well as Biomedical Engineering (Molecular Biophysics) all at Mayo Foundation. During his ten years at Mayo he helped raise over $30M in grants and alliance partnerships. He has scientific degrees from the University of East Anglia (UK), Southampton University (UK), University of California (USA), and received his Ph.D. from the University of Cambridge (UK) in biological mass spectrometry. He completed postdoctoral work at MIT (USA) and served as Associate Director of Mass Spectrometry at the MRC Toxicology Institute in London. He serves as a consultant to a number of analytical, pharmaceutical and biotech companies that have included IBM Life Sciences, Finnigan, MAT, Beckman Instruments, 3M Corporation, Aventis-Behring, Surromed, and Bristol Myers Squibb. He has published more than 225 research papers, and book chapters, has filed a number of patents, and has made over 600 presentations and seminars worldwide, in the area of analysis of complex biological mixtures, biomedical chromatography and mass spectrometry, and systems biology. He has contributed to the fields of genomics, proteomics, differential and functional proteomics, metabolomics, biomarkers, systems biology, nanofluidics, microchip-MS and the role of MS in the clinical diagnosis of disease. He has expertise in most elements of chromatography, mass spectrometry, NMR, SPR, and optical spectroscopy, informatics, biostatistics, bioinformatics, knowledge assembly and some elements of computational biology. More recently he has organized numerous international meetings on all aspects systems biology and biomarkers He is also the founder of the consulting company ProteosPec

Dr Amber Salzman

Dr. Amber Salzman currently serves as Senior Vice-President of R&D Information Technology at GlaxoSmithKline. In this role, Amber leads a transnational organization responsible for exploiting the expanding capabilities of information technology and knowledge management into pharmaceutical research and development, and ensuring efficient and effective use of technologies to drive productivity. During her 20 years with GlaxoSmithKline Pharmaceuticals Research & Development and legacy companies, Amber has established innovative management processes to support a transnational organization, optimized key business processes, and delivered critical business applications, and established an effective global computing environment. Amber has combined senior leadership and strategic capabilities along with consistent execution and delivery on a worldwide basis during her career at GSK. She has held increasingly senior leadership positions demonstrating creativity and analytical skills in improving the organization's effectiveness in accomplishing goals, and delivered essential strategies to evolve GlaxoSmithKline's use of technologies and related sciences. In addition to her role at GlaxoSmithKline, Amber leads a Medical Research Foundation taking an entrepreneurial approach to finding better therapies for people with Adrenoleukodystrophy leveraging innovative technologies such as stem cells and gene therapy. Prior to joining GSK, Amber worked at the Medical College of Pennsylvania. She holds a PhD in Mathematics from Bryn Mawr College and BA in Computer Science from Temple University.